Abstract
Extracorporeal ultrasound-guided high intensity focused ultrasound (USgFU) ablates solid lesions non-invasively. Limitations manifested in preclinical and clinical trials are discussed in brief. The ablation efficiency (necrosis rate) is low. Tissue responses are monitored in real time during USgFU treatment, based upon the appearance of hyperecho within the insonated volume. However, hyperecho does not necessarily indicate tissue necrosis, with a low specificity and negative predictive value. A preoperative treatment plan cannot predict the ablation outcome satisfactorily. A reflection interface in the travel path of therapeutic ultrasound obstructs the propagation, refocuses beams and shifts the focus or burns adjacent tissues. A diagnostic transducer is located in the center of a therapeutic one in a USgFU device; hence there is a blind field of the diagnostic transducer; tissues within this area cannot be constantly observed during HIFU insonation. The motion of an organ may shift a target lesion leading to untoward tissue damages. The drastic variance between tissue types/individuals is the greatest challenge for the standardization of USgFU treatment. The quantitatively clinical data of limitations are still unavailable, and USgFU therapy is with a low level of evidence from the perspective of evidence based medicine. Some potential solutions are introduced briefly. Key words: High intensity focused ultrasound, ultrasound imaging, ablation efficiency, real-time monitoring, treatment plan.
Highlights
Extracorporeal high intensity focused ultrasound (HIFU) non-invasively destructs a preselected volume within the body without harming overlying tissues via heat and cavitation, which has been applied for the treatment of a solid lesion
Monitoring tissue responses in real time is an advantage of ultrasound-guided high intensity focused ultrasound (USgFU), indicating that a treatment plan can be modified in due course
Clinical trials have demonstrated some limitations of USgFU, but systemically quantitative data are unavailable yet
Summary
Extracorporeal ultrasound-guided high intensity focused ultrasound therapy: Present limitations. Extracorporeal ultrasound-guided high intensity focused ultrasound (USgFU) ablates solid lesions noninvasively. The ablation efficiency (necrosis rate) is low. Tissue responses are monitored in real time during USgFU treatment, based upon the appearance of hyperecho within the insonated volume. Hyperecho does not necessarily indicate tissue necrosis, with a low specificity and negative predictive value. A preoperative treatment plan cannot predict the ablation outcome satisfactorily. A diagnostic transducer is located in the center of a therapeutic one in a USgFU device; there is a blind field of the diagnostic transducer; tissues within this area cannot be constantly observed during HIFU insonation. The quantitatively clinical data of limitations are still unavailable, and USgFU therapy is with a low level of evidence from the perspective of evidence based medicine.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
